BIO and Washington Biotechnology & Biomedical Association commend Washington State House and Senate for advancing legislation – HB 2326 and SB 6091 – designed to create pathway for substitution of interchangeable biologic medicines. Endorsed by broad coalition of biologic and biosimilar manufacturing companies, legislation represents significant step forward, ensures transparency and communication between patients and their treatment teams, and is consistent with BIO ...This story is related to the following:Trade Associations